All News
Filter News
Found 1,264 articles
-
Thermo Fisher Scientific Commences Tender Offer for All Outstanding Common Shares and ADSs of Olink
10/31/2023
Thermo Fisher Scientific Inc. and Olink Holding AB announced that Thermo Fisher has commenced the previously announced tender offer through a direct, wholly owned subsidiary of Thermo Fisher to acquire all of the outstanding common shares and all of the outstanding American Depositary Shares of Olink for $26.00 per common share and per ADS, in cash.
-
Aptose Presents Highlights from Clinical Update Webcast Featuring Latest Available Data on AML Drug Tuspetinib
10/30/2023
Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS) released highlights from a clinical update event held today, October 30, 2023, in conjunction with the European School of Haematology (ESH) 6th International Conference: Acute Myeloid Leukemia “Molecular and Translational”: Advances in Biology and Treatment, being held in Estoril, Portugal (the “ESH 2023 Conference”).
-
Thermo Fisher Scientific Reports Third Quarter 2023 Results
10/25/2023
Thermo Fisher Scientific Inc., the world leader in serving science, reported its financial results for the third quarter ended September 30, 2023.
-
Cyclo Therapeutics Announces Early Exercise of Warrants by Board Members, Management and a Significant Shareholder Resulting in Cash Proceeds of $2.4 Million
10/23/2023
Cyclo Therapeutics, Inc. today announced that it had entered into a securities purchase agreement with certain accredited investors (the “Investors”) to raise $2,359,584 in a private offering (the “Offering”).
-
U.S. Food and Drug Administration Approves BioMarin's VOXZOGO® (vosoritide) for Children Under 5 Years with Achondroplasia
10/20/2023
BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental New Drug Application (sNDA) for VOXZOGO® (vosoritide) to increase linear growth in pediatric patients with achondroplasia with open epiphyses (growth plates).
-
Foundation Medicine Announces Acceptance of 11 Abstracts at the 2023 European Society for Medical Oncology (ESMO) Annual Meeting
10/19/2023
Foundation Medicine, Inc., today announced that the company will present 11 abstracts demonstrating the value of high-quality biomarker tests to inform cancer care at the 2023 European Society for Medical Oncology (ESMO) Annual Meeting from October 20-24 in Madrid, Spain.
-
Thermo Fisher Scientific to Acquire Olink, a Leader in Next-Generation Proteomics
10/17/2023
Thermo Fisher Scientific Inc. and Olink Holding AB announced that their respective boards of directors have approved Thermo Fisher’s proposal to acquire Olink for $26.00 per common share in cash, representing $26.00 per American Depositary Share in cash.
-
BioMarin to Host Third-Quarter 2023 Financial Results Conference Call and Webcast on Wednesday, November 1, at 4:30pm ET
10/17/2023
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Jean-Jacques Bienaimé, Chairman and Chief Executive Officer of BioMarin, will host a conference call and webcast on Wednesday, November 1, at 4:30 p.m. ET to discuss third-quarter 2023 financial results and provide a general business update.
-
IMIDomics Establishes a License and Collaboration Partnership with the University of Barcelona to Advance Treatments for IMIDs
10/11/2023
IMIDomics Inc. today announced a strategic license and collaboration agreement with the University of Barcelona (UB).
-
Newfound Mechanism Suggests Drug Combination Could Starve Pancreatic Cancer
10/9/2023
A new combination of treatments safely decreased growth of pancreatic cancer in mice by preventing cancer cells from scavenging for fuel, a new study finds.
-
IMIDomics Announces Strategic Agreement with WuXi Biologics to Advance IMB1001 Antibody Development for Immune-Mediated Inflammatory Diseases
10/4/2023
IMIDomics Inc. today announced that it has entered into an agreement with WuXi Biologics, a global Contract Research, Development and Manufacturing Organization, aimed at accelerating the development and manufacturing of IMIDomics IMB1001.
-
Thermo Fisher Scientific to Hold Earnings Conference Call on Wednesday, October 25, 2023
10/3/2023
Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, announced that it will release its financial results for the third quarter 2023 before the market opens on Wednesday, October 25, 2023, and will hold a conference call on the same day at 8:30 a.m. EDT.
-
Twist Bioscience and IMIDomics Collaborate to Discover Antibodies for Applications in Immune-Mediated Inflammatory Diseases
9/27/2023
Twist Bioscience Corporation and IMIDomics, Inc. today announced a multi-program collaboration whereby Twist will utilize its antigen development capabilities and Library of Libraries to conduct antibody discovery activities against targets identified by IMIDomics.
-
BioMarin to Present Data Showing Long-Term Benefit of VOXZOGO® (vosoritide) on Growth in Children with Achondroplasia at 2023 European Society for Paediatric Endocrinology (ESPE) Meeting
9/21/2023
BioMarin Pharmaceutical Inc. today announced that new data on VOXZOGO ® (vosoritide) in children with achondroplasia will be presented at the 61st Annual European Society for Paediatric Endocrinology (ESPE) Meeting in The Hague, Netherlands.
-
Acino significantly expands presence and capabilities in Latin America through acquisition of M8 Pharmaceuticals
9/20/2023
Acino announced that it has entered into an agreement to acquire M8 Pharmaceuticals, a fast-growing specialty biopharmaceutical company, headquartered in Mexico City and focused on licensing, marketing, and distributing innovative and established medicines in Mexico and Brazil.
-
BioMarin to Present Innovative Pipeline at R&D Day on September 12th in New York
9/11/2023
BioMarin Pharmaceutical Inc. will update the investor community on the company's research and development portfolio, including early-stage product candidates and new indication opportunities with VOXZOGO and ROCTAVIAN.
-
Thermo Fisher Scientific and National Minority Quality Forum Collaborate to Make Clinical Research More Accessible to Historically Underserved Communities
9/7/2023
Thermo Fisher Scientific Inc., the world leader in serving science, and the National Minority Quality Forum, an independent not-for-profit research and education organization, announced a collaboration to help bring clinical research to historically underserved patient populations through NMQF’s Alliance for Representative Clinical Trials.
-
IMIDomics Inc. Secures Exclusive Worldwide Licensing Agreement with TNAX Biopharma Corporation for TNAX101A (IMB1001), A Promising Drug Candidate for Immune-Mediated Inflammatory Diseases
9/6/2023
IMIDomics Inc., a patient-centric drug discovery and development company focused on Immune-Mediated Inflammatory Diseases (IMIDs), today announced an exclusive license agreement with TNAX Biopharma Corporation (TNAX), an innovator in biotechnology.
-
Thermo Fisher Scientific to Present at Morgan Stanley 21st Annual Global Healthcare Conference on September 13, 2023
9/6/2023
Thermo Fisher Scientific to Present at Morgan Stanley 21st Annual Global Healthcare Conference on September 13, 2023.
-
BioMarin to Present Pipeline at Upcoming R&D Day on Tuesday, September 12th
9/6/2023
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN), a global biotechnology company dedicated to transforming lives through genetic discovery, will host an R&D Day at 8:00 a.m. ET on Tuesday, September 12, 2023.